171 related articles for article (PubMed ID: 27042160)
1. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.
Broecker-Preuss M; Becher-Boveleth N; Müller S; Mann K
Cancer Cell Int; 2016; 16():27. PubMed ID: 27042160
[TBL] [Abstract][Full Text] [Related]
2. Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.
Broecker-Preuss M; Viehof J; Jastrow H; Becher-Boveleth N; Fuhrer D; Mann K
J Exp Clin Cancer Res; 2015 Jul; 34(1):69. PubMed ID: 26198850
[TBL] [Abstract][Full Text] [Related]
3. Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 Mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells.
Broecker-Preuss M; Becher-Boveleth N; Mann K
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):324-30. PubMed ID: 26849668
[TBL] [Abstract][Full Text] [Related]
4. Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3'-oxime (7BIO).
Broecker-Preuss M; Becher-Boveleth N; Gall S; Rehmann K; Schenke S; Mann K
Cancer Cell Int; 2015; 15():97. PubMed ID: 26464561
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
6. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetic ABT-737 induces apoptosis in CD34
Rao J; Li F; Zhang RY; Zhou HH; Chen GA
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma.
Michalski M; Bauer M; Walz F; Tümen D; Heumann P; Stöckert P; Gunckel M; Kunst C; Kandulski A; Schmid S; Müller M; Gülow K
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371761
[TBL] [Abstract][Full Text] [Related]
9. ABT-263 induces G
Lin QH; Que FC; Gu CP; Zhong DS; Zhou D; Kong Y; Yu L; Liu SW
Acta Pharmacol Sin; 2017 Dec; 38(12):1632-1641. PubMed ID: 28713162
[TBL] [Abstract][Full Text] [Related]
10. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells.
Yu R; Lu Y; Yu R; Xie J; Zhou S
Cancer Manag Res; 2021; 13():953-963. PubMed ID: 33568941
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Mitsiades CS; Hayden P; Kotoula V; McMillin DW; McMullan C; Negri J; Delmore JE; Poulaki V; Mitsiades N
J Clin Endocrinol Metab; 2007 Dec; 92(12):4845-52. PubMed ID: 17848408
[TBL] [Abstract][Full Text] [Related]
13. Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells.
Weber A; Kirejczyk Z; Potthoff S; Ploner C; Häcker G
Transl Oncol; 2009 May; 2(2):73-83. PubMed ID: 19412422
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
Kim LH; Shin JA; Jang B; Yang IH; Won DH; Jeong JH; Chung TH; Cho NP; Cho SD
Arch Oral Biol; 2017 Jan; 73():1-6. PubMed ID: 27632413
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
Yokoyama T; Kohn EC; Brill E; Lee JM
Int J Oncol; 2017 Apr; 50(4):1064-1074. PubMed ID: 28350129
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
18. Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.
Ryu Y; Hall CP; Reynolds CP; Kang MH
Exp Biol Med (Maywood); 2014 Oct; 239(10):1390-402. PubMed ID: 24951472
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
20. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
